AgomAb Therapeutics NV (AGMB) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($447.2 million vs $383.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | ZURA |
|---|---|---|
| Share price | $9.08 | $4.00 |
| Market cap | $447.17M | $383.32M |
| 1-day change | -1.52% | -3.15% |
| YTD return | — | -23.66% |
| 1-year return | — | -3.61% |
| EPS (TTM) | $-2.08 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $7.44 |
| 52-week low | $7.97 | $3.15 |
| Distance from 52-week high | -49.05% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.87% | +350.00% |
| Average volume | 140.06K | 1.44M |
| Shares outstanding | 49.25M | 95.83M |
| Employees | 62 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
AGMB vs ZURA FAQ
Which is bigger, AgomAb Therapeutics NV or Zura Bio?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $447.17M compared with $383.32M for Zura Bio (ZURA).
Are AgomAb Therapeutics NV and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.